(Sharecast News) - The US Food and Drug Administration has approved the expanded usage of AstraZeneca's Koselugo drug to adults with neurofibromatosis type 1 (NF1) - a rare, progressive, genetic condition that can impact every organ system.
Koselugo, also known as selumetinib, is an oral treatment that inhibits the mitogen-activated...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE